What do systematic reviews say?

Antioxidants vs placebo

Antioxidant showed no clear difference in severe adverse events compared with placebo (low certainty).

• Pharmacological treatments for Friedreich ataxia 2016 · Cochrane Headline outcomes only
  RR 1 [0.07, 15]
  2 studies · 72 participants
  Low

Diflunisal vs placebo

It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).

• Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
  RR 2.06 [0.39, 10.87]
  1 study · 130 participants
  Very low

Patisiran vs placebo

Patisiran may leads to lower number of dropouts due to adverse events compared with placebo (low certainty).

• Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
  RR 0.33 [0.13, 0.82]
  1 study · 225 participants
  Low

Inotersen vs placebo

Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).

• Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
  RR 8.57 [1.16, 63.07]
  1 study · 172 participants
  Low

Tafamidis vs placebo

It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).

• Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
  RR 1.29 [0.3, 5.54]
  1 study · 128 participants
  Very low

Brain‐derived neurotrophic factor vs placebo

It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 1 [0.28, 3.54]
  1 study · 10 participants
  Very low

Cerebrospinal fluid filtration vs plasma exchange

It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).

• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 0.13 [0.01, 2.25]
  1 study · 37 participants
  Very low

Tripterygium polyglycoside vs corticosteroids

• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  GRADE not reported

Eculizumab vs placebo

Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).

• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 1.9 [0.34, 10.5]
  2 studies · 41 participants
  Low

Interferon beta‐1a vs placebo

It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 0.92 [0.23, 3.72]
  1 study · 19 participants
  Very low